Biography - Kevin Gregory-Evans

Kevin Gregory-Evans is currently Professor of Ophthalmology in the Faculty of Medicine, University of British Columbia, and holder of the Julia Levy BC Leadership Chair in Macular Research, Vancouver, Canada. Before 2009 he was Reader in Molecular Ophthalmology, Imperial College London, UK. He underwent clinical ophthalmology training at Moorfields Eye Hospital, London, UK and basic science research training with Professors Alan Bird and Shomi Bhattacharya (Institute of Ophthalmology, London, UK) and Professor Richard Weleber (Oregon Health Sciences University, Portland, Oregon, USA). In 1985 he achieved an MBBS, at St. Bartholomew's Medical School, University of London; in 1989 was awarded FRCS, Royal College of Surgeons and Physicians, Glasgow, UK; was awarded FRCOphth, Royal College of Ophthalmologists, London, in 1990; an MD (Res) in molecular biology in 1994, University of London; in 2009 was awarded a PhD in cell biology, University of London; and in 2012 was awarded the FRCSC of the Royal College of Physicians and Surgeons of Canada.

His research interests include novel approaches in the diagnosis and treatment of retinal disease. In total, Dr Gregory-Evans has published 82 peer-reviewed, original research articles, 18 peer-reviewed research review articles, and 9 book chapters. This has included basic science studies in molecular genetics, molecular therapeutics in model systems and stem cell therapeutics. Dr Gregory-Evans current lab includes two Research Associates, one Research Fellow, one Research Assistant and one post-doctoral student. In 1994 he reported one of the first localisations for a retinal disease gene and since then has reported on another 15 retinal disease genes. Dr Gregory-Evans has recently led two pre-clinical molecular therapeutic studies and two pre-clinical stem cell interventional studies. Clinical studies have included investigator-led descriptive studies in patients with retinal degeneration, corneal disease, cataract and glaucoma, and a number of investigator-led interventional studies in retinal degeneration, cataract and glaucoma. He has acted as a lead investigator for three pharma-led interventional studies: SUSTAIN (Study of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, Novartis Pharamceuticals); VIEW2 (VEGF trap-eye: investigation of efficiency and safety in wet AMD, Bayer Schering Pharma) and STAR (A Phase 2, Multicenter, Randomized, Double‑Masked, Placebo‑Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia, PTC Therapeutics).

In 2008 he was elected to the Macular Disease Advisory Group at the Royal College of Ophthalmologists, UK, to advise on setting up retinal disease treatment clinics throughout the UK. In 2006 he was elected an Examiner for post-graduate examinations of the Royal College of Ophthalmologists and between 2004 and 2009 was Theme Lead for undergraduate ophthalmology, Imperial College London, Currently, he is Council Member and Chairman, of the Research Infrastructure Working Group of the Vancouver Coastal Health Research Institute. He is also an active panel member for the Canadian Institutes of Health Research and the California Institute of Regenerative Medicine Panel, California, USA. He is an active speaker for lay audiences including: the Canadian National Institute for the Blind; the British Retinitis Pigmentosa Society; and the Royal National Institute for the Blind (UK) and the Foundation Fighting Blindness Canada. In 2013 he was awarded the Lang Medal by the Royal Society of Medicine (UK) for work on translational therapeutics for retinal diseases.